Research Themes

Health economics of melanoma and kidney disease


PhD, MScMed(Clin Epi)(Hons)

Prof Rachael Morton

Director, Health Economics & Health Technology Assessment

Professor Rachael Morton leads the Health Economics and Health Technology Assessment teams at the CTC. She specialises in trial-based and modelled economic evaluation, and elicitation of patient preferences using discrete choice experiments. Her research incorporates patient-centred and economic outcomes into clinical trials of diagnostic tests, new treatments and models of care to facilitate policy decision-making on the basis of cost-effectiveness.

Research interests

  • Health economics of melanoma
  • Chronic kidney disease.
  • Health equity in disadvantaged populations both in Australia and overseas.
  • Systematic reviews of economic evidence
  • Assessment of test evaluation and monitoring
  • Measurement of quality of life and well-being
  • End-of-life care

Teaching and supervision

Rachael is coordinator for one unit of study in health economics within the Masters programmes in the Sydney Medical School / School of Public Health: Health Economics in Trials (CLTR 5006). She coordinates short courses in health economics for government and industry and currently supervises five PhD candidates.


  • Within-trial and modelled economic evaluation
  • Preference elicitation
  • Outcomes assessment
  • Health equity
  • Chronic Kidney Disease
  • Melanoma and other cancers

Professional Associations

  • President, Health Services Research Association of Australia and New Zealand (HSRAANZ), member since 2011
  • Australian Clinical Trials Alliance (ACTA) member since 2016; Co-chair ACTA Reference Group – “Research Prioritisation: tools and criteria” since 2017
  • Health Economists’s Clinical Trials Alliance (HECTA) – Founding member since 2016
  • International Society for Pharmacoeconomic and Outcomes Research (ISPOR), member since 2009
  • International Health Economics Association (IHEA) Program Chair 2018/19, member since 2008
  • Health Economists Study Group – UK (HESG) member since 2010
  • Cochrane Equity Methods Group member since 2013
  • Australia and New Zealand Society of Nephrology (ANZSN) member since 1996
  • Australia and New Zealand Melanoma Trials Group (ANZMTG) Founding member since 2003
  • Expert Reference Group member, Renal node - Joanna Briggs Institute member since 2012


View Rachael's publications.